Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04629248 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
A Phase 3 study of Primary Membranous Nephropathy, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 20
- Study locations
NCT04629248: Active Phase 3 study of Primary Membranous Nephropathy, sponsored by Hoffmann-La Roche.
NCT04629248 is a Phase 3 study of Primary Membranous Nephropathy that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 142 participants, above the 119-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04629248, a Phase 3 study of Primary Membranous Nephropathy, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Acetaminophen
- DRUG Methylprednisolone
- DRUG Diphenhydramine
- DRUG Tacrolimus
Study Locations (20)
Other
- Organizacion Medica de Investigacion - Buenos Aires
- CINME - Buenos Aires
- Hospital Britanico Buenos Aires - Buenos Aires
- Peking University First Hospital - Beijing
- Sichuan Provincial People's Hospital - Chengdu
- The 1st Affiliated hospital of Fujian Medical University - Fuzhou
- Nanfang Hospital, Southern Medical University - Guangzhou
São Paulo
- Hospital de Base de Sao Jose do Rio Preto - São José do Rio Preto
- Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos - São Paulo
- Hospital das Clinicas - FMUSP - São Paulo
California
- Kaiser Permanente - San Francisco Medical Center - San Francisco
Colorado
- University of Colorado in Denver-Anschutz Medical Campus - Aurora
Florida
- Accel Research Sites; Mid-Florida Kidney and Hypertension Care - Altamonte Springs
Iowa
- University of Iowa - Iowa City
Michigan
- Henry Ford Hospital - Detroit
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2021-06-25 |
| Est. Completion | 2027-12-21 |
| Phase | Phase 3 |
What the registry record for NCT04629248 still lists
NCT04629248 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, above the 119-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT04629248 names 20 study sites across 12 states, led by Other, São Paulo, California.
Frequently Asked Questions
What is clinical trial NCT04629248 about?
NCT04629248 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy". This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
What is the current status of trial NCT04629248?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2021-06-25. Estimated completion is 2027-12-21.
What conditions does trial NCT04629248 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT04629248?
The interventions under investigation include: Obinutuzumab (DRUG), Acetaminophen (DRUG), Methylprednisolone (DRUG), Diphenhydramine (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT04629248?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04629248 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04629248's enrollment target sits among peer trials
142 5th of 8 higher than 4 of 8 other Primary Membranous Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Membranous Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RECRUITING · Phase 3
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI